Wockhardt Targets Mid-2026 India Launch for Breakthrough Antibiotic 'Zaynich'

July 1, 2025 – Wockhardt is on track to market Zaynich, its new antibiotic that fights multidrug-resistant gram-negative infections, in India by mid-2026. This is after the successful completion of global Phase III clinical trials and the submission of India-specific data to the DCGI. Chairman Habil Khorakiwala said that approval is expected in nine to ten months, which will provide for a strong launch in the US.

Global Rollout Strategy: India First, US to Follow

In the next two to three months, Wockhardt will ask the government in the United States to approve its new antibiotic Zaynich. The company hopes to commercialise the medicine in the U.S. market by early FY27 if the review process goes smoothly.

The business plan for Zaynich will be different in each area. Wockhardt plans to sell the medication directly in the U.S. using its commercial infrastructure. In Europe, however, it will use an out-licensing strategy to speed up market entry. Chairman Habil Khorakiwala didn’t say how much money the company expects to make, but he did say that the number of patients who could benefit from the new antibiotics in the U.S. could grow from 80,000 to 1,00,000 over the next three to four years. This is because there is a growing need for antibiotics that work against drug-resistant infections.

Strong Results from Compassionate Use Program

Zaynich has already been administered to 51 patients under compassionate use protocols 48 in India and 3 in the US. The treatment, given safely over a three-month period, showed encouraging results. “Virtually every patient recovered from the infection,” said Khorakiwala, adding that the recovery rate was over 90%.

Expansion of Antibiotic Portfolio and Revenue Targets

Wockhardt has also brought a new antibiotic called Miqnaf to the Indian market, together with Zaynich. The company thinks this would be very valuable. Wockhardt has redesigned the antibiotic EMROK, which had problems when it first came out, and this year, they want to quadruple its sales to ₹80–100 crore.

The company plans to double its sales from ₹3,000 crore to ₹6,000 crore over the next three years. By FY27, profit margins should also go up from the present 12-13% to more than 20%.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations